BackZhejiang Wecome Pharmaceutical Company Limited Overview

Zhejiang Wecome Pharmaceutical Company Limited Inventory

Latest inventory for 300878.SZ: $58M.

Get informed when a big investor buys or sells

+ Follow
Inventory
$57.83M
↓ 30.78% YoYΔ $-25.72M vs prior year quarter

Peer trimmed avg / median

Loading

Zhejiang Wecome Pharmaceutical Company Limited Inventory History

Loading

Zhejiang Wecome Pharmaceutical Company Limited vs. peers: Inventory Comparison

Loading

Zhejiang Wecome Pharmaceutical Company Limited Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ) FAQ

Zhejiang Wecome Pharmaceutical Company Limited's inventory stands at $58M as of September 2026. That compares with $84M in the prior-year period — down 30.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Zhejiang Wecome Pharmaceutical Company Limited reported $58M in inventory versus $84M a year earlier — a 30.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $84M in the prior-year period — down 30.8% year over year. Sustained growth in inventory can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Zhejiang Wecome Pharmaceutical Company Limited's inventory evolved across reporting periods, while the comparison chart places 300878.SZ next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, inventory is commonly used to spot outliers. Zhejiang Wecome Pharmaceutical Company Limited's reading of $58M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.